BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25946081)

  • 1. Sexual Dimorphism in MAPK-Activated Protein Kinase-2 (MK2) Regulation of RANKL-Induced Osteoclastogenesis in Osteoclast Progenitor Subpopulations.
    Herbert BA; Valerio MS; Gaestel M; Kirkwood KL
    PLoS One; 2015; 10(5):e0125387. PubMed ID: 25946081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation.
    Valerio MS; Herbert BA; Griffin AC; Wan Z; Hill EG; Kirkwood KL
    Bone; 2014 Mar; 60():16-25. PubMed ID: 24269279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens.
    Mensah KA; Ritchlin CT; Schwarz EM
    J Cell Physiol; 2010 Apr; 223(1):76-83. PubMed ID: 20039274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of MKP-1 in lipopolysaccharide-induced osteoclast formation through CXCL1 and CXCL2.
    Valerio MS; Herbert BA; Basilakos DS; Browne C; Yu H; Kirkwood KL
    Cytokine; 2015 Jan; 71(1):71-80. PubMed ID: 25261746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
    Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
    Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
    Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
    Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation.
    Sharma SM; Bronisz A; Hu R; Patel K; Mansky KC; Sif S; Ostrowski MC
    J Biol Chem; 2007 May; 282(21):15921-9. PubMed ID: 17403683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
    Hyeon S; Lee H; Yang Y; Jeong W
    Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis.
    Zhao D; Shi Z; Warriner AH; Qiao P; Hong H; Wang Y; Feng X
    PLoS One; 2014; 9(7):e102706. PubMed ID: 25032991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ampelopsis brevipedunculata extract prevents bone loss by inhibiting osteoclastogenesis in vitro and in vivo.
    Kim JY; Park SH; Oh HM; Kwak SC; Baek JM; Lee MS; Rho MC; Oh J
    Molecules; 2014 Nov; 19(11):18465-78. PubMed ID: 25397737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
    Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
    J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
    Gong W; Dou H; Liu X; Sun L; Hou Y
    Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine enhances osteoclast differentiation and maturation through p38 MAP kinase/Mitf and DC-STAMP/CtsK and TRAP pathway.
    Choi J; Choi SY; Lee SY; Lee JY; Kim HS; Lee SY; Lee NK
    Cell Signal; 2013 May; 25(5):1222-7. PubMed ID: 23434822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
    Shim KS; Ma CJ; Kim DS; Ma JY
    J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of CD26 signaling inhibits human osteoclast development.
    Nishida H; Suzuki H; Madokoro H; Hayashi M; Morimoto C; Sakamoto M; Yamada T
    J Bone Miner Res; 2014 Nov; 29(11):2439-55. PubMed ID: 24821427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes.
    Hirata K; Taki H; Shinoda K; Hounoki H; Miyahara T; Tobe K; Ogawa H; Mori H; Sugiyama E
    Biol Pharm Bull; 2010; 33(1):133-7. PubMed ID: 20045951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.